2026– date –
-
Yole Group Forecasts Advanced Packaging Market to Double to Over $120 Billion by 2031, Driven by AI and HPC Demand
Yole Group (via advancedpackaging.news) France Overview Yole Group's latest report projects the global advanced packaging market to more than double from $55 billion in 2025 to over $120 billion by 2031, fueled by next-generation AI and ... -
TSMC Pledges Additional $100 Billion for Arizona Fabs, Total U.S. Investment Reaches $265 Billion to Boost Advanced Chip Manufacturing
Supply Chain Dive USA Overview TSMC has committed an additional $100 billion to its semiconductor manufacturing and packaging facilities in Arizona, elevating its total U.S. investment to $265 billion. This expansion includes four new ad... -
AI Chip Packaging Bottleneck Intensifies: NVIDIA Explores Intel EMIB Amid TSMC CoWoS Shortage, Amkor Commits $7B to Arizona
The Economy Japan Overview The burgeoning AI chip market faces a critical bottleneck in advanced packaging, particularly with TSMC's CoWoS technology, prompting NVIDIA to reportedly consider Intel's EMIB for future GPU production. This s... -
TIDES USA 2026: Oligonucleotide CMC Innovations Address Manufacturing and Analytical Bottlenecks
Informa Connect USA Overview The TIDES USA 2026 summit focused on oligonucleotide CMC (Chemistry, Manufacturing, and Controls) innovations, discussing crucial process, analytical, and CMC strategies for clinical and commercial success. K... -
Eli Lilly’s Triple G-Agonist Retatrutide Succeeds in Two More Phase III Trials for Obesity and Type 2 Diabetes
GlobalData USA Overview Eli Lilly's GLP-1/GIP/Glucagon (GCG) triple receptor agonist, retatrutide, met primary endpoints in two additional Phase III trials (TRIUMPH-2 and TRIUMPH-3) for type 2 diabetes and obesity patients with establish... -
Blood-Brain Barrier Drug Delivery Summit (B3DD) Convenes to Overcome CNS Therapeutic Hurdles
News-Medical.net USA Overview The Blood-Brain Barrier Drug Delivery Summit (B3DD) addressed critical challenges in CNS drug delivery, focusing on bypassing the brain's selective permeability. Advanced DDS research into nanoparticles, lip... -
FDA Approves Sanofi’s Subcutaneous Isatuximab (Sarclisa Escena) for Multiple Myeloma, Enhancing Patient Convenience
Drugs.com USA Overview The U.S. FDA has approved Sanofi's subcutaneous formulation, Sarclisa Escena (isatuximab-irfc), for multiple myeloma, significantly improving administration convenience for patients. This new formulation reduces tr... -
FDA Approves Celcuity’s Breakthrough Gedatolisib for Advanced Breast Cancer with Priority Review Designation
Life Science Daily News USA Overview The FDA approved Celcuity's first-in-class PI3K/AKT/mTOR pathway inhibitor, gedatolisib, for advanced breast cancer on its PDUFA date of July 17, 2026. This approval, following Priority Review and Bre... -
Boehringer Ingelheim Initiates Phase II Trial for BI 3034701, a Potential First-in-Class Triple Receptor Agonist for Obesity
Boehringer Ingelheim Germany Overview Boehringer Ingelheim has launched a Phase II clinical trial for BI 3034701, an investigational triple GLP-1/GIP/NPY2 receptor agonist targeting patients with obesity and overweight. This molecule rep... -
bioRxiv Preprint: TLS11a Aptamer-Functionalized LNP Platform for Hepatocyte-Preferential mRNA Delivery and CRISPR LDLR-KO Model Established
bioRxiv USA Overview A preprint published in bioRxiv details the design and validation of an aptamer-functionalized lipid nanoparticle (LNP) platform for hepatocyte-preferential genome editing delivery, demonstrated using a multilevel-va...
